Aclaris Therapeutics, Inc. (ACRS)

1.1700 +0.0100 (+0.86%) At close: 04:00PM EDT

Aclaris Therapeutics, Inc.

701 Lee Road
Suite 103
Wayne, PA 19087
United States
484 324 7933
https://www.aclaristx.com

Sector(s): Healthcare
Industry: Diagnostics & Research
Full Time Employees: 86

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Neal S. Walker D.O., M.D.	Co-Founder, President, Chairman & Interim CEO	73.5k	N/A	1970
Mr. Kevin Balthaser	Chief Financial Officer	581.52k	N/A	1988
Dr. Joseph Monahan Ph.D.	Chief Scientific Officer	492.43k	N/A	1957
Mr. James Loerop	Chief Business Officer	570k	N/A	1965
Mr. Matthew Rothman J.D.	General Counsel & Corporate Secretary	N/A	N/A	N/A
Dr. Jon Jacobsen Ph.D.	Senior Vice President of Chemistry	N/A	N/A	N/A
Mr. Steve Tucker	Senior Vice President of Project Leadership	N/A	N/A	N/A
Mr. Ajay Aggarwal M.B.A., M.D.	Senior Vice President of Clinical Development	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Corporate Governance

Aclaris Therapeutics, Inc.’s ISS Governance QualityScore as of October 1, 2024 is 10. The pillar scores are Audit: 7; Board: 9; Shareholder Rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.